Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9) 9
female (6) 6
male (6) 6
middle aged (6) 6
adult (5) 5
drug therapy (5) 5
drug therapy, combination (5) 5
dosage and administration (4) 4
hepatitis c (4) 4
hepatitis c, chronic - drug therapy (4) 4
hiv infections - drug therapy (4) 4
index medicus (4) 4
abridged index medicus (3) 3
anti-hiv agents - therapeutic use (3) 3
antiviral agents (3) 3
antiviral agents - administration & dosage (3) 3
antiviral agents - adverse effects (3) 3
cd4-positive t-lymphocytes - virology (3) 3
hepacivirus - genetics (3) 3
hepatitis c, chronic - virology (3) 3
hiv (3) 3
hiv infection (3) 3
hiv protease inhibitors - therapeutic use (3) 3
infections (3) 3
interferon-alpha - administration & dosage (3) 3
medicine, general & internal (3) 3
polyethylene glycols - administration & dosage (3) 3
protease inhibitors (3) 3
research (3) 3
ribavirin (3) 3
sofosbuvir (3) 3
telaprevir (3) 3
uridine monophosphate - analogs & derivatives (3) 3
adolescent (2) 2
aged (2) 2
anti-hiv agents (2) 2
anti-hiv agents - administration & dosage (2) 2
antiviral agents - therapeutic use (2) 2
benzoates - pharmacokinetics (2) 2
biological sciences (2) 2
boceprevir (2) 2
ccr5 (2) 2
ccr5 receptor antagonists (2) 2
clinical trials (2) 2
combination (2) 2
dna, viral - genetics (2) 2
double-blind method (2) 2
drug interactions (2) 2
genotype (2) 2
haart therapy (2) 2
health aspects (2) 2
hepatitis (2) 2
highly active antiretroviral therapy (2) 2
hiv infections - immunology (2) 2
hiv protease inhibitors - administration & dosage (2) 2
hiv-1 - isolation & purification (2) 2
hiv-1 - physiology (2) 2
human-immunodeficiency-virus (2) 2
in-vivo (2) 2
indinavir - administration & dosage (2) 2
indinavir - therapeutic use (2) 2
interferon (2) 2
interferon-alpha - therapeutic use (2) 2
internal medicine (2) 2
lamivudine - administration & dosage (2) 2
lamivudine - therapeutic use (2) 2
latency (2) 2
liver cirrhosis (2) 2
pharmacology & pharmacy (2) 2
physiological aspects (2) 2
piperazines - pharmacokinetics (2) 2
polyethylene glycols - therapeutic use (2) 2
primary infection (2) 2
psi-7977 (2) 2
recombinant proteins - administration & dosage (2) 2
recombinant proteins - therapeutic use (2) 2
replication (2) 2
resistance (2) 2
reverse transcriptase inhibitors - administration & dosage (2) 2
reverse transcriptase inhibitors - therapeutic use (2) 2
ribavirin - administration & dosage (2) 2
ribavirin - therapeutic use (2) 2
rna, viral - blood (2) 2
spiro compounds - pharmacokinetics (2) 2
treatment outcome (2) 2
uridine monophosphate - administration & dosage (2) 2
uridine monophosphate - therapeutic use (2) 2
viral nonstructural proteins - antagonists & inhibitors (2) 2
viremia (2) 2
virus integration (2) 2
virus latency (2) 2
virus replication (2) 2
virus-infection (2) 2
zidovudine - administration & dosage (2) 2
zidovudine - therapeutic use (2) 2
activation (1) 1
administration, oral (1) 1
adverse events (1) 1
aids (1) 1
analysis (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
by Kowdley, Kris V, Dr and Lawitz, Eric, MD and Crespo, Israel, MD and Hassanein, Tarek, MD and Davis, Mitchell N, MD and DeMicco, Michael, MD and Bernstein, David E, MD and Afdhal, Nezam, MD and Vierling, John M, MD and Gordon, Stuart C, MD and Anderson, Jane K, PhD and Hyland, Robert H, DPhil and Dvory-Sobol, Hadas, PhD and An, Di, PhD and Hindes, Robert G, MD and Albanis, Efsevia, MD and Symonds, William T, PharmD and Berrey, M Michelle, MD and Nelson, David R, MD and Jacobson, Ira M, MD
Lancet, The, ISSN 0140-6736, 2013, Volume 381, Issue 9883, pp. 2100 - 2107
Summary Background The uridine nucleotide analogue sofosbuvir is a selective inhibitor of hepatitis C virus (HCV) NS5B polymerase. We assessed the safety and... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | TRIPLE THERAPY | BOCEPREVIR | TELAPREVIR | ADVERSE EVENTS | LIFE | Uridine Monophosphate - administration & dosage | Puerto Rico | United States | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Ribavirin - administration & dosage | Uridine Monophosphate - analogs & derivatives | Female | Drug Therapy, Combination | Hepatitis C, Chronic - genetics | Sofosbuvir | Complications and side effects | Peginterferon alfa-2a | Dosage and administration | Research | Hepatitis C | Drug therapy | Ribavirin | Hepatitis | Genotype & phenotype | Infections | Liver cirrhosis | Drug dosages
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
by Lawitz, Eric, Prof and Lalezari, Jay P, MD and Hassanein, Tarek, Prof and Kowdley, Kris V, Prof and Poordad, Fred F, Prof and Sheikh, Aasim M, MBBS and Afdhal, Nezam H, Prof and Bernstein, David E, Prof and DeJesus, Edwin, MD and Freilich, Bradley, MD and Nelson, David R, Prof and Dieterich, Douglas T, Prof and Jacobson, Ira M, Prof and Jensen, Donald, Prof and Abrams, Gary A, MD and Darling, Jama M, MD and Rodriguez-Torres, Maribel, MD and Reddy, K Rajender, Prof and Sulkowski, Mark S, Prof and Bzowej, Natalie H, MD and Hyland, Robert H, DPhil and Mo, Hongmei, PhD and Lin, Ming, PhD and Mader, Michael, MS and Hindes, Robert, MD and Albanis, Efsevia, MD and Symonds, William T, PharmD and Berrey, Michelle M, MD and Muir, Andrew, Prof
Lancet Infectious Diseases, The, ISSN 1473-3099, 2013, Volume 13, Issue 5, pp. 401 - 408
Summary Background Protease inhibitors have improved treatment of infection with hepatitis C virus (HCV), but dosing, a low barrier to resistance, drug... 
Infectious Disease | PSI-7977 | INFECTIOUS DISEASES | PLUS RIBAVIRIN | VIRUS-INFECTION | TELAPREVIR | BOCEPREVIR | INHIBITORS | Recombinant Proteins - therapeutic use | Uridine Monophosphate - administration & dosage | Nausea - chemically induced | Humans | Middle Aged | Hepatitis C, Chronic - virology | Hepacivirus - pathogenicity | Male | Secondary Prevention | Polyethylene Glycols - therapeutic use | Young Adult | Time Factors | Ribavirin - administration & dosage | Adult | Female | Headache - chemically induced | Uridine Monophosphate - therapeutic use | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | RNA, Viral - analysis | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Drug Therapy, Combination - methods | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Adolescent | Liver Cirrhosis - pathology | Aged | Hepacivirus - classification | Sofosbuvir | Care and treatment | Protease inhibitors | Proteases | Gastrointestinal diseases | Clinical trials | Product development | Genetic aspects | Interferon | Hepatitis C | Health aspects | Liver cirrhosis | Viral antigens
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial
by Gane, Edward J, Dr and Roberts, Stuart K, MD and Stedman, Catherine AM, MD and Angus, Peter W, Prof and Ritchie, Brett, MD and Elston, Rob, PhD and Ipe, David, MS and Morcos, Peter N, PharmD and Baher, Linda, BS and Najera, Isabel, PhD and Chu, Tom, MD and Lopatin, Uri, MD and Berrey, M Michelle, MD and Bradford, William, MD and Laughlin, Mark, MD and Shulman, Nancy S, MD and Smith, Patrick F, PharmD
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9751, pp. 1467 - 1475
Summary Background Present interferon-based standard of care treatment for chronic hepatitis C virus (HCV) infection is limited by both efficacy and... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | VIRUS | TELAPREVIR | INDUCIBLE PROTEIN-10 | LIVER FIBROSIS | IN-VIVO | RESISTANCE | DYNAMICS | RIBAVIRIN | PEGINTERFERON | ITMN-191 | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Recombinant Proteins | Adult | Deoxycytidine - adverse effects | Female | Drug Therapy, Combination | Lactams - adverse effects | Double-Blind Method | Administration, Oral | Deoxycytidine - administration & dosage | Lactams - administration & dosage | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Interferon-alpha - administration & dosage | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Viral Nonstructural Proteins - antagonists & inhibitors | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Clinical trials | Dosage and administration | Protease inhibitors | Hepatitis C | Drug therapy | Studies | Stock options | Meetings | Mortality | RNA polymerase | Tropical diseases | Antiviral activity
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
by Gane, Edward J and Stedman, Catherine A and Hyland, Robert H and Ding, Xiao and Svarovskaia, Evguenia and Symonds, William T and Hindes, Robert G and Berrey, M. Michelle
The New England Journal of Medicine, ISSN 0028-4793, 01/2013, Volume 368, Issue 1, pp. 34 - 44
In this small, preliminary study of sofosbuvir, a nucleotide inhibitor of HCV polymerase, treatment with sofosbuvir and ribavirin, without peginterferon, was... 
GENOTYPE 1 | PSI-7977 | MEDICINE, GENERAL & INTERNAL | VIRUS-INFECTION | THERAPY | REPLICATION | RESISTANCE | REPLICON RNA-SYNTHESIS | COMBINATION | TREATMENT-NAIVE PATIENTS | PROTEASE | Recombinant Proteins - therapeutic use | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | Recombinant Proteins - adverse effects | Polyethylene Glycols - therapeutic use | Viral Load | Adult | Female | RNA, Viral - metabolism | Uridine Monophosphate - adverse effects | Drug Therapy, Combination | Uridine Monophosphate - therapeutic use | Hepacivirus - isolation & purification | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Hemoglobins - metabolism | Genotype | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - blood | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Interferon-alpha - adverse effects | Viral Nonstructural Proteins - antagonists & inhibitors | Sofosbuvir | Drugs | Dose-response relationship (Biochemistry) | Antiviral agents | Usage | Patient outcomes | Dosage and administration | Product/Service Evaluations | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Hepatitis | Interferon | Infections | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Early Establishment of a Pool of Latently Infected, Resting CD4+T Cells during Primary HIV-1 Infection
by Tae-Wook Chun and Delphine Engel and M. Michelle Berrey and Theresa Shea and Lawrence Corey and Anthony S. Fauci
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 7/1998, Volume 95, Issue 15, pp. 8869 - 8873
The presence of latently infected, resting CD4 T cells carrying replication-competent HIV-1 has been demonstrated in chronically infected individuals who are... 
T lymphocytes | Highly active antiretroviral therapy | HIV | Viremia | Viruses | Disease reservoirs | Infections | Symptoms | HIV 1 | Blood plasma | Primary infection | HAART therapy | Latency | RESPONSES | PLASMA | MULTIDISCIPLINARY SCIENCES | latency | IN-VIVO | primary infection | AIDS | HUMAN-IMMUNODEFICIENCY-VIRUS | Physiological aspects | Research | T cells | HIV infection
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Effect of interleukin-2 on the pool of latently infected, resting CD4 + T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy
by Davey, Richard T and Metcalf, Julia A and Fischette, Maria and Berrey, M. Michelle and Mican, JoAnn M and Fauci, Anthony S and Lane, H. Clifford and Hallahan, Claire W and Dybul, Mark and Corey, Lawrence and Park, Sohee and Engel, Delphine and Mizell, Stephanie B and Kovacs, Joseph A and Chun, Tae-Wook
Nature Medicine, ISSN 1078-8956, 06/1999, Volume 5, Issue 6, pp. 651 - 655
The size of the pool of resting CD4(+) T cells containing replication-competent HIV in the blood of patients receiving intermittent interleukin (IL)-2 plus... 
MEDICINE, RESEARCH & EXPERIMENTAL | ACTIVATION | CONTROLLED TRIAL | BIOCHEMISTRY & MOLECULAR BIOLOGY | ANTIRETROVIRAL THERAPY | HUMAN-IMMUNODEFICIENCY-VIRUS | COMBINATION | CELL BIOLOGY | INDIVIDUALS | VIREMIA | CANCER-PATIENTS | REPLICATION | HIV ERADICATION | Virus Replication - drug effects | HIV-1 - pathogenicity | Cross-Sectional Studies | HIV-1 - drug effects | Humans | Interleukin-2 - therapeutic use | RNA, Viral - blood | Lymph Nodes - virology | HIV Protease Inhibitors - therapeutic use | Interleukin-2 - pharmacology | Anti-HIV Agents - therapeutic use | HIV Infections - drug therapy | Lymphocyte Count - drug effects | CD4-Positive T-Lymphocytes - virology | CD4-Positive T-Lymphocytes - drug effects | Highly active antiretroviral therapy | Interleukin-2 | Physiological aspects | Drug therapy | HIV (Viruses) | HIV infection | Health aspects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Evaluation of the Drug Interaction Potential of Aplaviroc, a Novel Human Immunodeficiency Virus Entry Inhibitor, Using a Modified Cooperstown 5 + 1 Cocktail
by Johnson, Brendan M and Song, Ivy H and Adkison, Kimberly K and Borland, Julie and Fang, Lei and Lou, Yu and Berrey, M. Michelle and Nafziger, Anne N and Piscitelli, Stephen C and Bertino, Joseph S
The Journal of Clinical Pharmacology, ISSN 0091-2700, 05/2006, Volume 46, Issue 5, pp. 577 - 587
Aplaviroc is a novel CCR5 antagonist, a class of compounds under investigation as viral entry inhibitors for the treatment of human immunodeficiency virus... 
drug interactions | biomarker | CCR5 | Cytochrome P450 | Biomarker | Drug interactions | CHINESE | cytochrome P450 | COMBINED PHENOTYPIC ASSESSMENT | CCR5 ANTAGONIST | S-MEPHENYTOIN | XANTHINE-OXIDASE | PHARMACOKINETICS | CYP2D6 GENE | PHARMACOLOGY & PHARMACY | POLYMERASE CHAIN-REACTION | METABOLIZING-ENZYMES | DISEASE PROGRESSION | Benzoates - adverse effects | Humans | Middle Aged | Omeprazole - blood | Aryl Hydrocarbon Hydroxylases - genetics | Male | Spiro Compounds - adverse effects | Caffeine - pharmacokinetics | Drug Interactions | Adult | Female | Dextromethorphan - pharmacokinetics | Anti-HIV Agents - blood | Piperazines - pharmacokinetics | Piperazines - blood | CCR5 Receptor Antagonists | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Anti-HIV Agents - adverse effects | Caffeine - blood | Omeprazole - pharmacokinetics | Midazolam - pharmacokinetics | Piperazines - adverse effects | Spiro Compounds - pharmacokinetics | Aryl Hydrocarbon Hydroxylases - metabolism | Warfarin - pharmacokinetics | Benzoates - blood | Midazolam - blood | Anti-HIV Agents - pharmacokinetics | Dextromethorphan - urine | Spiro Compounds - blood | Warfarin - blood | Benzoates - pharmacokinetics | Antiviral agents | Dosage and administration | Research | Drug therapy | HIV infection | Anti-HIV agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text The effects of ritonavir and lopinavir/ritonavir on the pharmacokinetics of a novel CCR5 antagonist, aplaviroc, in healthy subjects
by Adkison, Kimberly K and Shachoy‐Clark, Anne and Fang, Lei and Lou, Yu and Otto, Vicky R and Berrey, M. Michelle and Piscitelli, Stephen C
British Journal of Clinical Pharmacology, ISSN 0306-5251, 09/2006, Volume 62, Issue 3, pp. 336 - 344
Aims This study assessed the effects of the CYP3A inhibitors lopinavir/ritonavir (LPV/r) on the steady‐state pharmacokinetics (PK) of aplaviroc (APL), a CYP3A4... 
lopinavir | CCR5 | aplaviroc | drug interaction | ritonavir | Drug interaction | Aplaviroc | Ritonavir | Lopinavir | HIV | MECHANISM | SAFETY | SAQUINAVIR | PHARMACOLOGY & PHARMACY | PROTEASE INHIBITORS | Humans | Middle Aged | Pyrimidinones - therapeutic use | Rats | Male | Spiro Compounds - pharmacokinetics | Animals | Drug Interactions | Adolescent | Ritonavir - therapeutic use | Adult | Female | HIV Infections - drug therapy | Pyrimidinones - pharmacology | Ritonavir - pharmacology | Mice | Piperazines - pharmacokinetics | Drug Combinations | Benzoates - pharmacokinetics | CCR5 Receptor Antagonists | Antiviral agents | Analysis | Anti-HIV agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection
by Tae-Wook Chun and Delphine Engel and M. Michelle Berrey and Theresa Shea and Lawrence Corey and Anthony S. Fauci
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 07/1998, Volume 95, Issue 15, pp. 8869 - 8873
The presence of latently infected, resting CD4 + T cells carrying replication-competent HIV-1 has been demonstrated in chronically infected individuals who are... 
Lamivudine - administration & dosage | Indinavir - administration & dosage | Virus Latency | Humans | HIV Protease Inhibitors - administration & dosage | Reverse Transcriptase Inhibitors - administration & dosage | Virus Integration | HIV Protease Inhibitors - therapeutic use | Zidovudine - administration & dosage | Anti-HIV Agents - administration & dosage | HIV Infections - immunology | HIV-1 - physiology | Virus Replication | HIV-1 - isolation & purification | Lamivudine - therapeutic use | Anti-HIV Agents - therapeutic use | HIV Infections - drug therapy | Zidovudine - therapeutic use | Reverse Transcriptase Inhibitors - therapeutic use | CD4-Positive T-Lymphocytes - virology | DNA, Viral - genetics | Drug Therapy, Combination | Indinavir - therapeutic use | Biological Sciences | primary infection | HAART therapy | latency
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Diagnosing oral manifestations of sexually transmitted diseases
by Berrey, M.M and Corey, L
Consultant, ISSN 0010-7069, 1997, Volume 37, Issue 5, pp. 1243 - 1244
Journal Article
Details down arrow
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.